Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
One Percent Rule Checklist For Safer Forex Trading Risk 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
IRVINE, Calif., April 21, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against BioAmber Inc. (“BioAmber” or the “Company”) (NYSE:BIOA). Investors who purchased shares pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017; and/or on the open market from January 23, 2017 through March 16, 2017 inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the May 17, 2017 lead plaintiff motion deadline.
If you purchased BioAmber shares during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at [email protected].
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
The complaint states that throughout the Class Period, BioAmber made materially false and/or misleading statements and/or failed to disclose that a large customer of the Company that was expected to purchase $2.8 million of succinic acid in the fourth quarter of 2016 postponed the order to 2017; and as a result, the Company’s statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When this information reached the public, the stock price of BioAmber fell, which caused investors harm.
If you wish to learn more about this lawsuit, or if you have questions regarding this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
